Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,598,021
  • Shares Outstanding, K 210,543
  • Annual Sales, $ 450,710 K
  • Annual Income, $ -88,880 K
  • EBIT $ 76 M
  • EBITDA $ 66 M
  • 60-Month Beta 0.91
  • Price/Sales 3.66
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 56.73% (-6.59%)
  • Historical Volatility 44.11%
  • IV Percentile 69%
  • IV Rank 29.66%
  • IV High 118.54% on 01/02/25
  • IV Low 30.67% on 01/21/25
  • Expected Move (DTE 12) 0.47 (6.16%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 1,874
  • Volume Avg (30-Day) 1,591
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 59,504
  • Open Int (30-Day) 51,678
  • Expected Range 7.12 to 8.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.04
  • Number of Estimates 4
  • High Estimate 0.07
  • Low Estimate 0.00
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +130.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.70 +13.20%
on 11/25/25
8.17 -7.10%
on 12/04/25
+0.42 (+5.86%)
since 11/05/25
3-Month
6.00 +26.50%
on 10/14/25
8.31 -8.72%
on 09/08/25
-0.68 (-8.22%)
since 09/05/25
52-Week
6.00 +26.50%
on 10/14/25
11.31 -32.89%
on 06/04/25
-0.25 (-3.19%)
since 12/05/24

Most Recent Stories

More News
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...

BCRX : 7.59 (-3.07%)
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.  (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the...

BCRX : 7.59 (-3.07%)
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

-- BioCryst’s Acquisition of Astria Expected to Close in the First Quarter of 2026 -- -- Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned...

ATXS : 12.93 (-1.45%)
BCRX : 7.59 (-3.07%)
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

–   Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – –  ORLADEYO oral granules demonstrated...

BCRX : 7.59 (-3.07%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...

BCRX : 7.59 (-3.07%)
BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Jefferies Global Healthcare Conference...

BCRX : 7.59 (-3.07%)
BioCryst: Q3 Earnings Snapshot

BioCryst: Q3 Earnings Snapshot

BCRX : 7.59 (-3.07%)
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)—  —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107...

BCRX : 7.59 (-3.07%)
BioCryst to Report Third Quarter 2025 Financial Results on November 3

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results...

BCRX : 7.59 (-3.07%)
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Astria Therapeutics...

ATXS : 12.93 (-1.45%)
BCRX : 7.59 (-3.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

3rd Resistance Point 8.34
2nd Resistance Point 8.14
1st Resistance Point 7.86
Last Price 7.59
1st Support Level 7.38
2nd Support Level 7.18
3rd Support Level 6.90

See More

52-Week High 11.31
Fibonacci 61.8% 9.28
Fibonacci 50% 8.66
Fibonacci 38.2% 8.03
Last Price 7.59
52-Week Low 6.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar